Midostaurin
Orphan DrugFDA Approved
Contents
Description
Midostaurin is a kinase inhibitor used in the treatment of acute myeloid leukemia (AML) with certain genetic mutations. It works by blocking the activity of specific enzymes that promote cancer cell growth.
Indications & Therapeutic Use
Acute Myeloid Leukemia (AML) with FLT3 mutation
Global Availability (3 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Midostaurin — GNH India
12 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Midostaurin products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Midostaurin
| Generic Name | Midostaurin |
| Brands | 1 brand available |
| Active Ingredient | Midostaurin |
| Drug Class | Acute Myeloid Leukemia (AML) with FLT3 mutation |
| Manufacturer | Novartis |
| Dosage Forms | Capsule, 25 mg |
| Medical Code | L01XE26 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00651261 |
| Countries | 3 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations4 Validated Nodes